Skip to main content

Table 1 Effect of intravitreal injection of PP-001 on R14-induced relapsing EAU in rats

From: Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells

  Vehicle PP-001
Mean max. clin. uveitis score primary disease (score 0 – 4 ± SE) 2.6 ± 0.1 2.7 ± 0.1
Mean max. clin. uveitis score at
day of injection (score 0 – 4 ± SE)
0.5 ± 0.1 0.4 ± 0.1
Total no. of relapses post injection until day 6 20 6
No. of eyes with multiple relapses 2 0
No. of eyes with relapses 18 out of 30 eyes (60%)* 6 out of 29 eyes (21%)*
Relapses/animals 11/15 (73%)* 5/15 (33%)*
Mean max. uveitis score/relapse (score 0 – 4 ± SE) 1.1 ± 0.1 1.2 ± 0.3
Mean duration of relapse (days ± SE) 1.45 ± 0.11 1.17 ± 0.17
Mean appearance of first relapse (days post injection ± SE) 3.4 ± 0.5 4.3 ± 0.9
Mean severity of uveitis post injection until day 6 (± SE) 2.22 ± 0.25* 1.34 ± 0.22*
  1. “Mean severity of uveitis” is the mean of daily uveitis scores calculated over a certain period of time. One eye of the PP-001-treated group (rat 7/PP-001, see Fig. 1) was perforated during injection and not considered. Data are pooled from two independent experiments, Exp. 1, n = 10; Exp. 2, n = 5 rats/group. *p < 0.05